Get the Stockscreener App
167.55
0.42%
-0.70
After Hours:
167.09
-0.46
-0.27%
Natera Inc stock is traded at $167.55, with a volume of 899.35K.
It is down -0.42% in the last 24 hours and up +9.80% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$168.25
Open:
$166.98
24h Volume:
899.35K
Relative Volume:
0.66
Market Cap:
$22.56B
Revenue:
$1.53B
Net Income/Loss:
$-214.69M
P/E Ratio:
-95.20
EPS:
-1.76
Net Cash Flow:
$-43.68M
1W Performance:
+1.41%
1M Performance:
+9.80%
6M Performance:
-0.39%
1Y Performance:
+51.74%
1-Day Range:
$165.45
$168.00
1-Week Range:
$161.39
$169.17
52-Week Range:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
167.55 | 22.56B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
390.26 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
195.75 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.59 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.09 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
154.10 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Where are the Opportunities in (NTRA) - news.stocktradersdaily.com
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance
Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - marketscreener.com
Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com
Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia
Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India
Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa
Natera's Signatera test to be covered under Medicare - MSN
Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus
Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus
Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com
Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha
Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com
Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus
Natera announces Medicare coverage for Signatera MRD assay - TipRanks
Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia
Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus
Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus
Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma
Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com
Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st
Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World
Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha
NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus
NTRA Price Target Increased by Piper Sandler After Quarterly Res - GuruFocus
Natera, Inc. (NTRA): A Bull Case Theory - MSN
Trend Tracker for (NTRA) - news.stocktradersdaily.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):